U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Hysteroscopes and Gynecology Laparoscopes - Submission Guidance for a 510(k)
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Hysteroscopes and Gynecology Laparoscopes - Submission Guidance for a 510(k) March 1996

Download the Final Guidance Document
Final
Docket Number:
FDA-2020-D-0957
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

This guidance was written prior to the February 27, 1997 implementation of FDA's Good Guidance Practices, GGP's. It does not create or confer rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both. This guidance will be updated in the next revision to include the standard elements of GGP's.

This document outlines the information to be submitted in a 510(k) premarket notification for hysteroscopes and gynecologic laparoscopes. For devices that differ significantly from those already on the market, FDA may require additional information specific to those differences. This document is intended as a companion to the Substantial Equivalence Comparison Chart released in April 1995 (see Appendix A), and it replaces our previous March 25, 1994, “Hysteroscopes & Laparoscopes, Insufflators & Other Related Instrumentation: Submission Requirements for a 510(k).”

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-0957.

Back to Top